Barbara Eichhorst, MD from University of Cologne, Cologne, Germany discusses updates in current clinical trials being undertaken in the field of chronic lymphocytic leukemia (CLL). Treatment of patients with 17p deletions have shown very good response rates, with a median progression-free survival of 13 months. Dr Eichhorst also discusses the HELIOS Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory CLL (EudraCT No. 2012-000600-150). The bendamustine and rituximab plus ibrutinib arm of this study has shown continuous improvement in the response quality and minimal residual negativity (MRD). Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Updates from current CLL clinical trials
